Wyeth-Ayerst Effexor XR Shows Efficacy In Long-Term GAD From Weeks 2-28
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A pivotal, 28-week trial of Wyeth-Ayerst’s Effexor XR (venlafaxine) in the long-term treatment of generalized anxiety disorder (GAD) showed that patients had statistically significant improvements versus placebo for all primary and secondary endpoints by week two, and that those improvements lasted throughout the study, investigators reported in the June 21 issue of the Journal of the American Medical Association.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class